Press releases

NORTH CHICAGO, Ill., Dec. 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 33^rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, 2015. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m. Central time.

NORTH CHICAGO, Ill., Dec. 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, Jan. 6, 2015. Richard A. Gonzalez, chairman and chief executive officer, will take part in a question and answer session at 2:15 p.m. Central time.

NORTH CHICAGO, Ill., Dec. 19, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is the only FDA-approved regimen that contains three distinct mechanisms of action - NS5A inhibitor, NS3/4A protease inhibitor and a non-nucleoside NS5B polymerase inhibitor - that work together to attack the virus at three separate stages of the disease lifecycle to inhibit it from reproducing.

NORTH CHICAGO, Ill., Dec. 7, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) presented during an oral presentation at the American Society of Hematology's 56^th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.¹ In the study, the venetoclax group showed an overall response rate (ORR) of 15.5 percent, with one patient achieving a complete response and four patients achieving a complete response with incomplete blood count recovery.

NORTH CHICAGO, Ill., Nov. 21, 2014 /PRNewswire/ -- The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's (NYSE: ABBV) investigational, all-oral, interferon-free treatment of VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) with or without ribavirin (RBV) for patients with genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infection. The European Commission will review the opinions and make a final decision sometime in the first quarter of 2015.

NORTH CHICAGO, Illinois, Nov. 21, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapore's Tuas Biomedical Park. The facility will expand the company's global operations for small molecule and biologics manufacturing, providing increased capacity for compounds within AbbVie's immunology and oncology pipelines. This reflects progress from AbbVie's announcement for manufacturing investment in Asia earlier this year.

NORTH CHICAGO, Ill., Nov. 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American Society of Hematology Annual Meeting (ASH), December 6-9, in San Francisco. Data will be highlighted in 13 accepted abstracts, including several oral presentations detailing new trial results from the venetoclax program in acute myelogenous leukemia, elotuzumab in multiple myeloma, and duvelisib in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.  

NORTH CHICAGO, Ill., Nov. 14, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.

NORTH CHICAGO, Ill., Nov. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA^® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 – 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.

BOSTON, Nov. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.